| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
The molecular classification of multiple myeloma.
|
Blood
|
2006
|
8.77
|
|
2
|
Thalidomide and hematopoietic-cell transplantation for multiple myeloma.
|
N Engl J Med
|
2006
|
7.89
|
|
3
|
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.
|
Blood
|
2006
|
7.63
|
|
4
|
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells.
|
Blood
|
2002
|
5.47
|
|
5
|
Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.
|
Blood
|
2006
|
3.64
|
|
6
|
Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.
|
Blood
|
2010
|
3.41
|
|
7
|
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.
|
Br J Haematol
|
2007
|
3.41
|
|
8
|
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities.
|
Blood
|
2008
|
3.22
|
|
9
|
Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation.
|
Blood
|
2006
|
3.17
|
|
10
|
Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences.
|
J Clin Oncol
|
2010
|
3.09
|
|
11
|
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.
|
Blood
|
2009
|
3.02
|
|
12
|
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
|
Blood
|
2007
|
2.91
|
|
13
|
Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.
|
Br J Haematol
|
2008
|
2.64
|
|
14
|
Long-term outcome results of the first tandem autotransplant trial for multiple myeloma.
|
Br J Haematol
|
2006
|
2.32
|
|
15
|
CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.
|
Clin Cancer Res
|
2008
|
2.13
|
|
16
|
Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications.
|
J Clin Oncol
|
2007
|
2.13
|
|
17
|
A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.
|
Clin Cancer Res
|
2013
|
2.02
|
|
18
|
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.
|
Blood
|
2012
|
1.93
|
|
19
|
High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2.
|
Proc Natl Acad Sci U S A
|
2010
|
1.78
|
|
20
|
Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies.
|
Blood
|
2005
|
1.71
|
|
21
|
HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy.
|
Blood
|
2014
|
1.68
|
|
22
|
Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms.
|
J Clin Oncol
|
2010
|
1.66
|
|
23
|
Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.
|
Blood
|
2011
|
1.61
|
|
24
|
A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma.
|
Blood
|
2011
|
1.60
|
|
25
|
Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease.
|
Blood
|
2014
|
1.59
|
|
26
|
Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.
|
Blood
|
2009
|
1.56
|
|
27
|
Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma.
|
Blood
|
2007
|
1.55
|
|
28
|
Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling.
|
Clin Cancer Res
|
2007
|
1.53
|
|
29
|
TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3.
|
Br J Haematol
|
2009
|
1.51
|
|
30
|
Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103.
|
Cytotherapy
|
2010
|
1.50
|
|
31
|
Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989.
|
Blood
|
2007
|
1.45
|
|
32
|
Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease.
|
Br J Haematol
|
2006
|
1.44
|
|
33
|
Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation.
|
Br J Haematol
|
2008
|
1.44
|
|
34
|
Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics.
|
Br J Haematol
|
2007
|
1.28
|
|
35
|
Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease.
|
Blood
|
2008
|
1.14
|
|
36
|
Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data.
|
Haematologica
|
2012
|
1.09
|
|
37
|
The Arkansas approach to therapy of patients with multiple myeloma.
|
Best Pract Res Clin Haematol
|
2007
|
1.09
|
|
38
|
Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone.
|
Stem Cells
|
2011
|
1.07
|
|
39
|
DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.
|
J Clin Oncol
|
2003
|
1.06
|
|
40
|
Highly activated and expanded natural killer cells for multiple myeloma immunotherapy.
|
Haematologica
|
2012
|
1.05
|
|
41
|
Completion of premaintenance phases in total therapies 2 and 3 improves clinical outcomes in multiple myeloma: an important variable to be considered in clinical trial designs.
|
Cancer
|
2008
|
1.04
|
|
42
|
Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning.
|
Exp Hematol
|
2003
|
1.02
|
|
43
|
Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival.
|
Blood
|
2009
|
1.01
|
|
44
|
Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients.
|
J Immunother
|
2015
|
1.01
|
|
45
|
Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3.
|
Blood
|
2013
|
1.00
|
|
46
|
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.
|
Blood
|
2013
|
0.99
|
|
47
|
Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma.
|
Cancer Res
|
2005
|
0.99
|
|
48
|
International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols.
|
Cancer
|
2010
|
0.97
|
|
49
|
Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1.
|
Br J Haematol
|
2008
|
0.96
|
|
50
|
Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease.
|
Am J Hematol
|
2013
|
0.95
|
|
51
|
Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients.
|
Br J Haematol
|
2010
|
0.95
|
|
52
|
Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1.
|
Clin Cancer Res
|
2012
|
0.91
|
|
53
|
High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patients.
|
Cancer
|
2008
|
0.90
|
|
54
|
Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma.
|
J Immunother
|
2007
|
0.90
|
|
55
|
NY-ESO-1 immunotherapy for multiple myeloma.
|
Leuk Lymphoma
|
2006
|
0.88
|
|
56
|
In multiple myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genes.
|
Genes Chromosomes Cancer
|
2014
|
0.86
|
|
57
|
Eruptive cherry hemangiomatosis associated with multicentric Castleman disease: a case report and diagnostic clue.
|
JAMA Dermatol
|
2013
|
0.85
|
|
58
|
Siltuximab for multicentric Castleman disease.
|
Expert Rev Hematol
|
2014
|
0.83
|
|
59
|
Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profile.
|
Br J Haematol
|
2009
|
0.83
|
|
60
|
Superior 12-year survival after at least 4-year continuous remission with tandem transplantations for multiple myeloma.
|
Clin Lymphoma Myeloma
|
2006
|
0.82
|
|
61
|
Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levels.
|
PLoS One
|
2013
|
0.81
|
|
62
|
Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy.
|
Haematologica
|
2008
|
0.79
|
|
63
|
NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity.
|
Exp Hematol
|
2013
|
0.77
|
|
64
|
Allografting or autografting for myeloma.
|
N Engl J Med
|
2007
|
0.75
|
|
65
|
A compound T60A and V122I heterozygosity in the transthyretin gene causing early onset severe cardiac amyloidosis.
|
Amyloid
|
2014
|
0.75
|